US pharmaceutical giant Bristol Myers Squibb (BMS, NYSE: BMY) has announced the market launch of Sotyktu (deucravacitinib) in China, marking a significant milestone for the treatment of moderate to severe plaque psoriasis. Sotyktu is recognized as the world’s first and only TYK2 allosteric inhibitor, suitable for patients eligible for systemic therapy or phototherapy.
Deucravacitinib received approval as a Category 1 drug in China in October 2023 for adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. The drug is now being made available in multiple physical pharmacies across the country and is expected to be listed on JD.com, expanding access for patients in need.- Flcube.com
